The one step RT-qPCR kits market is estimated to reach USD 111.1 million in 2024. It is estimated that revenue will increase at a CAGR of 4.9% between 2024 and 2034. The market is anticipated to reach USD 180.0 million by 2034.
Public health emergency of COVID-19 highlighted the need for rapid diagnostic solution, which could be used by common individual. One-step RT-qPCR kits are widely recognized as one of the most effective methods for detecting viruses, leading to a spike in demand for these kits.
Advancements in molecular biology and product launch of testing kits with improved reagents for examples, TaqMan Real-time PCR assays, contributed to the market revenue. Further increasing prevalence of viral infections excluding COVID-19 and other seasonal infections have led to demand for diagnostic solutions.
With the increased focus on research and development the demand of one step RT-qPCR kits within a research setting has also surged.
One Step RT-qPCR Kits Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 105.7 million |
| Estimated Size, 2024 | USD 111.1 million |
| Projected Size, 2034 | USD 180.0 million |
| Value-based CAGR (2024 to 2034) | 4.9% |
The demand for One-Step RT-qPCR testing grew as genetic research increased, the need for fast diagnostic solutions emerged, and high-throughput demands set in. The widespread use of RT-qPCR, extending to cancer research, drug discovery, and epidemiological studies, has contributed to this demand.
Many projects, like the Human Genome Project, unraveled critical genes related to diseases such as neurodegenerative disorders, diabetes, and cancer. Most importantly, the above result should be confirmed by RT-qPCR.
During the COVID-19 pandemic, how the Broad Institute collaborated with educational institutions in processing more than 1.1 million tests was just a perfect example of how important the use of RT-qPCR technology is in controlling public health crises.
Infectious diseases and public health emergencies have aggravated the demand for diagnostics that assure accuracy at all levels of health care with rapid speed. One-Step RT-qPCR proved quite ideal for these requirements. It detects extremely infectious pathogens such as HIV, malaria, and influenza with great sensitivity and specificity, fast enough to make a great difference in the treatment and outbreak control.
The technological innovation of equipment miniaturization has made this possible and brought the One-Step RT-qPCR test closer to many people, even in remote or resource-poor areas.
However, the market faces competition from alternative technologies. The benefits of CRISPR-based diagnostics, NGS, and isothermal amplification techniques, like LAMP, regarding speed, cost-efficiency, and holistic genetic analysis, challenges the adoption of RT-qPCR method in some cases diagnostics.
Despite this, the continued advancements and applications of one step RT-qPCR ensure its ongoing relevance and significant role in modern diagnostics.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increased Demand for High-Throughput Testing in Research has fueled the One Step RT-qPCR Kits Market growth
Genetic mutation studies, the study of epigenetics, and gene expression profiling have been very much in vogue for the last few years. Human Genome projects and other related projects have the potential for the identification of a variety of genes responsible for cancer, diabetes, and neurological disorders. Such findings of this type of research must be validated in a variety of population groups by using the RT-qPCR kits.
The Broad Institute of MIT and Harvard collaborated with 108 private and public educational institutions throughout Massachusetts and the surrounding region during the COVID-19 pandemic to facilitate regular COVID-19 testing for students, staff, and faculty members. It refashioned its high-tech, CLIA-certified automated laboratory into a high-throughput COVID-19 test-processing center that processed more than 1.1 million tests.
High-throughput RT-qPCR is also considered indispensable in epidemiological studies, as found in the Global Virome Project, while characterizing and identifying unknown viruses circulating in wildlife and livestock. Indeed, high-throughput RT-qPCR is essential to perform such ambitious tasks of screening and analyzing large volumes of samples.
RT-qPCR techniques are also in wide use in drug discovery studies for measuring variations in gene expression after treatment with drugs. Automation enables screening of big libraries of small molecules, hence increasing throughput in the drug development process. Applications of RT-qPCR range from biomarker detection to efficacy testing of drugs, and pharmacokinetic testing.
Along with the fast-growing demand for high-throughput testing by RT-qPCR, so increases the demand for one-step RT-qPCR kits. High-throughput capability and efficiency make one-step kits particularly suitable for such applications.
Increased demand for Multiplexing Capabilities drives for One Step RT-qPCR Kits Market
Urbanization, climatic change, and intercontinental travel have contributed to the spread of viral infection. It results in increased population density, which is a factor that drives the transmission rates of viruses. This also provides an expanded habitat for disease vectors, which are usually insects like mosquitoes. Global travel hastens the spread of viruses. Adding to the complexity is a host of emerging and re-emerging infections.
One-step RT-qPCR kits with multiplex capability can detect various pathogens or genetic targets within a single assay. These kits enable comprehensive results at better economy and efficiency. Most of the viruses that cause respiratory infection present with overlapping symptoms and are usually difficult to diagnose based on clinical presentation.
One of the most important advantages of multiplexing is finding the exact etiology when similar symptoms can be caused by different pathogens.
This trend of multiplexing is not only limited to infectious diseases but has also entered into other areas such as oncology. In cancer diagnostics, multiplexed RT-qPCR assays are being developed for the detection of multiple biomarkers at one time.
All this becomes highly important in personalized medicine, which gives an overall genetic profile of tumors for targeted therapy. Several firms have already launched multiplex One-Step RT-qPCR kits owing to the increasing demand for multiplex assays that further fuel market growth with enhanced and efficient diagnostic possibilities.
Surge in the demand for Point-of-Care Testing (POCT) Provides an Opportunity for Market Growth
Point-of-Care testing provides immediate results on-site that can be availed for timely clinical decision-making. This rapid diagnostic capability is critical in emergencies where rapid diagnosis will lead to prompt treatment and improvement in patient outcomes, reducing the transmission of infectious diseases.
The pandemic underlined this need, and the demand for rapid and reliable tests increased, showing the importance of efficient tools like One-Step RT-qPCR due to its real-time outcome.
Conditions like HIV, malaria, and influenza belong to that category where identifications are urgently needed for proper treatment to begin with to avoid outbreaks. The potentiality of One-Step RT-qPCR is extremely appropriate in achieving high levels of sensitivity and specificity for detecting these particular pathogens at the point of care.
Therefore, it ensures a faster and more accurate diagnosis hence being highly contributory in line with the treatment and also in the control of diseases.
Such advance in assay design and miniaturization of equipment has made the use of One-Step RT-qPCR tests possible in field environments other than a typical laboratory setting, even in remote and resource-limited settings. This new accessibility is critical for the management of diseases among populations lacking centralized laboratory resources, thereby enabling correct and timely diagnostics where most needed.
Therefore, increasing demand for fast diagnostics, infectious diseases on the rise, and technological advances have substantially given a boost to the tremendous growth of the One-Step RT-qPCR market, which signifies growing demand for point-of-care testing solutions.
Competition from Alternative Technologies can hinder the Market Growth
CRISPR technology, which was originally developed to edit genes, was adapted for diagnostic purposes using platforms such as SHERLOCK (Specific High-sensitivity Enzymatic Reporter unlocking) and DETECTR [DNA Endonuclease-Targeted CRISPR Trans Reporter]. These CRISPR-based diagnostics enable very fast and specific detection of nucleic acids.
The new assays, for example, using CRISPR developed at the Broad Institute, have been shown to detect viral RNA with similar sensitivity compared to RT-qPCR but in a fraction of the time without the use of expensive thermocycling equipment. The speed, simplicity, and lower comparative cost of such assays make them exceptionally attractive for point-of-care settings and could reduce reliance on traditional RT-qPCR methods.
Next-Generation Sequencing or NGS is an important emerging alternative to RT-qPCR, because of more extensive genetic material analysis. While RT-qPCR can detect only certain sequences, NGS may sequence the whole genomes simultaneously and give extensive information about the presence of a pathogen, its genetic makeup, mutations, and variants.
The isothermal amplification techniques, including LAMP, have emerged as a rival to RT-qPCR. The tests involving LAMP amplify nucleic acids in one single, constant temperature without needing thermal cycling equipment.
This approach makes the process simpler and less encumbering with respect to equipment costs, increasing speed and accessibility, especially in resource-poor settings. Hence the growing adoption of alternative technologies has led to hindrance to the market growth.
The one step RT-qPCR kits industry recorded a CAGR of 4.9% between 2019 and 2023. According to the industry, one step RT-qPCR kits generated USD 105.7 million in 2023, up from USD 63.5 million in 2019.
The Covid-19 pandemic led to the high demand for accurate and rapid testing solutions. This urgency led to development and widespread adoption of one step RT-qPCR kits. Due to which the quick processing of multiple samples where made possible.
With growing concern over the reliability of test results manufacturers are focusing on improving the accuracy and reducing variation. Manufactures are enhancing reagent formulations and refining protocols to minimize variability and increase confidence in test outcomes. The growing prevalence of other viral infection such as pneumonia, Hepatitis B, and seasonal ailment such common cold have also contributed to the market growth
With the advancement in the technology the emphasis have been placed on automation and high-throughput capabilities. Laboratories are searching for solutions that can integrate into existing workflows, allowing for more efficient processing of samples. Strategic collaborations and partnerships among key players are also becoming more common as companies seek to leverage each other's strengths to innovate and expand their market reach.
Geographically, while North America and Europe remain leaders due to established research infrastructures, the Asia-Pacific region is emerging as a significant growth area, driven by increasing investments in healthcare and rising awareness of molecular diagnostics. Overall, these trends indicate a dynamic market landscape poised for continued evolution and growth.
Principal Consultant
Companies in the Tier 1 sector account for 82.1% of the global market, ranking them as the dominant players in the industry. Tier 1 player’s offer a wide range of products related to research laboratories, have an established industry presence, offer continuous innovation, and have a significant influence in the field. Having financial resources that enables them to enhance their research and development efforts and expand into new markets.
A strong brand recognition and a loyal customer base provide them with a competitive advantage. Prominent companies within Tier 1 include Thermo Fisher Scientific Inc., Qiagen, and Takara Bio Inc.
Tier 2 players dominate the industry with a 9.9% market share. Tier 2 firms have a strong focus on a specific technology and a substantial presence in the industry, but they have less influence than Tier 1 firms. The players are more competitive when it comes to pricing and target niche markets.
New products and services will also be introduced into the industry by Tier 2 companies. Tier 2 companies include Bio-Rad Laboratories, Inc, Promega Corporation, New England Biolabs, and Fortis Life Sciences.
Compared to Tiers 1 and 2, Tier 3 companies have smaller revenue spouts and less influence. Those in Tier 3 have smaller work force and limited presence across the globe. Prominent players in the tier 3 category are Quantabio, BIO-HELIX, MP Biomedicals, Avantor, Inc., Intact Genomics, Inc., Solis BioDyne, Applied Biological Materials Inc, and TIANGEN Biotech (Beijing) Co., Ltd
The section below covers the industry analysis for the one step RT-qPCR kits market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia, Western Europe, Eastern Europe, and Middle East and Africa (MEA), is provided.
The United States is anticipated to remain at the forefront in North America through 2034. India is projected to witness a CAGR of 7.5% from 2024 to 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| Canada | 3.7% |
| Germany | 5.0% |
| France | 4.8% |
| Italy | 4.6% |
| China | 5.3% |
| India | 7.5% |
| Japan | 5.9% |
The USA one step RT-qPCR kits industry is expected to grow at a 3.0% CAGR from 2024 to 2034. The United States government is promoting innovation in molecular diagnostics. FDA has undertaken Breakthrough Devices Program. The program aims to speed up the approval of breakthrough products. The FDA's approved new rapid antigen tests for COVID-19 detection during the pandemic.
This served a crucial role in pandemic response efforts. The pandemic also fueled the adoption of at-home testing kits. This step has empowered the individual to conduct diagnosis from the comfort of their home and paved the way for proactive healthcare.
Further advancements in technology such as the integration of AI and ML into the diagnostic process can enhance the interpretation capability when complex data are involved. Laboratories are also adopting automation technologies.
This reduces human error, streamlines the process, and enables the lab to handle large volumes of samples. Hence the innovation and adoption of novel technologies have led to the growth of the USA one step RT-qPCR kits market.
A CAGR of 5.3% is predicted for the forecast period. The rise in the COVID-19 pandemic increased the demand for accurate and fast diagnostic solutions. Healthcare providers required a product that could deliver results within a few minutes.
The number of cases were high and a large volume of samples had to be tested. One-step RT-qPCR kits allow for quick detection of viral infections. Since China has been investing in developing quality healthcare infrastructure the life expectancy has increased. This has resulted in a rise in geriatric population. Which in turn resulted in a rise in demand for rapid diagnostic solutions. Because older patients are more prone to chronic infections.
Studies have shown that rapid diagnostic tests are essential for malaria control in China-Myanmar border areas. Also, the Chinese government has launched various initiatives aimed at controlling infectious diseases, which include mass screening programs that rely heavily on rapid diagnostic tests. The cumulative effect of the pandemic and government initiatives has led to demand for rapid diagnostic solutions which fueled the market growth in China.
Japan has a high geriatric population around 28% of citizens are 65 years or above. Japan also has a strong healthcare infrastructure where in quality and efficiency are of prime importance. As per the World Bank data of 2021, the healthcare expenditure of the country reached 10.8% of its GDP.
Also the prevalence of infectious disease is increasing. Both the above factor has led to huge demand for diagnostic solutions. One-step RT-qPCR kits deliver rapid, precise results. The Japanese healthcare system emphasizes preventive care, encouraging regular screenings and check-ups, further boosting the demand for innovative diagnostic technologies.
Owing to the high demand for diagnosis solutions the market for one step RT-qPCR kits is growing as they offer high specificity and sensitivity. Novel technologies such as AI and ML are being integrated into the diagnostic technologies which make the interpretation of results more accurate.
This improved capability further expands its potential application, hence owing to the combined effect of the aforementioned factors the One-step RT-qPCR kits market is growing within Japan. Between 2024 and 2034, Japan is expected to expand at a CAGR of 5.9%.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
A description of the leading segments in the industry is provided in this section. The virus detection segment held 41.5% of the value share in 2024. Based on the end user, hospitals held 38.1% of the market in 2024.
| Application | Virus Detection |
|---|---|
| Value Share (2024) | 41.5% |
The recent pandemic has exposed some deficiencies in the health care infrastructure, including a lack of point-of-care rapid diagnostic solutions that can be used by anyone with or without monitoring by a healthcare professional.
Since the cases scaled up exponentially during the pandemic, there was a need for diagnostic solution on large scale. The risk of the pandemic has subdued but the routine examination as a preventive measure for the re-emergence of COVID-19 still contributes a considerable volume of tests.
In addition to the Covid-19 virus, there were other viruses like Hepatitis B, Herpes simplex Virus, Pneumonia, Measles, etc. that added to the total burden in the world. Seasonal viruses like Seasonal influenza, common cold, etc. present the kind of loads that are necessary to be diagnosed daily and thus, due to the pandemic effect as well as viral burden globally, one-step RT-qPCR kits have been taken up across the world for virus detection.
| End User | Hospitals |
|---|---|
| Value Share (2024) | 38.0% |
The government is taking initiative to build healthcare infrastructure across the countries. This initiative involves establishing hospital settings. Also, the hospitals have the highest capacity to handle large patient volumes and deliver quality healthcare. The need for healthcare equipment, machines, and consumables including the one-step RT-qPCR kit is also high within the hospitals.
Many medium and large-scale hospitals have in-house laboratories for diagnostic testing. In certain conditions, routine period testing is required to monitor the progress of the patient. Hence the above-mentioned factors cumulatively contribute to a significant number of tests being performed within the hospital setting, which in turn requires the large-scale consumption of testing kits including the one-step RT-qPCR kits.
One step RT-qPCR offers rapid diagnostic capability which further increases their adoption. Hence the hospital segment is dominating the end-user segment of the market.
Established market players are acquiring emerging small players to leverage their technological expertise. This move enhanced the company’s product portfolio. Also they get an upper hand in the competitive market. Due to the surge in demand for rapid diagnostic kits during Covid-19 pandemic many company launched diagnostic kits to meet the market demand and leverage the opportunity.
Establishing product approval in multiple countries is another prominent strategies implemented by the market leader to increase the number of revenue streams.
Recent Industry Developments in the One Step RT-qPCR Kits Market
In terms of reaction, the industry is segmented into 25 Rxn one step RT-qPCR kits, 50 Rxn one step RT-qPCR kits, 100 Rxn one step RT-qPCR kits, 200 Rxn one step RT-qPCR kits, 400 Rxn one step RT-qPCR kits, 500 Rxn one step RT-qPCR kits, 1000 Rxn one step RT-qPCR kits, and above 1000 Rxn one step RT-qPCR kits.
In terms of application, the industry is bifurcated into chickenpox immunization and herpes zoster immunization.
In terms of end users, the industry is segregated into hospitals, clinics, and others.
In terms of end users, the industry is segregated into hospitals, clinics, and others.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, the Middle East, and Africa have been covered in the report.
One step RT-qPCR kits industry is expected to increase at a CAGR of 4.9% between 2024 and 2034.
The 400 Rxn one-step RT-qPCR kits segment is expected to occupy a 26.9% market share in 2024.
The market for one step RT-qPCR kits is expected to reach USD 180.0 million by 2034.
The United States is forecast to see a CAGR of 3.0 % during the assessment period.
The key players in the one step RT-qPCR kits industry include Thermo Fisher Scientific Inc., QIAGEN, Takara Bio Inc., Bio-Rad Laboratories, Inc., Promega Corporation, New England Biolabs, Fortis Life Sciences, Quantabio, BIO-HELIX, MP Biomedicals, Avantor, Inc., Intact Genomics, Inc, Solis BioDyne, Applied Biological Materials Inc, Merck KGAA, TIANGEN Biotech(Beijing)Co., Ltd, EnzyQuest, Canvax, Zymo Research Corporation, NZYtech, Abbexa, Boca Scientific Inc, and GeneDireX, Inc.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Pricing Analysis 5. Global Market Size USD Million Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. By Reaction 6.2. By Application 6.3. By Detection 6.4. By End User 6.5. By Region 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Reaction 7.1. 25 Rxn One-step RT-qPCR kits 7.2. 50 Rxn One-step RT-qPCR kits 7.3. 100 Rxn One-step RT-qPCR kits 7.4. 200 Rxn One-step RT-qPCR kits 7.5. 400 Rxn One-step RT-qPCR kits 7.6. 500 Rxn One-step RT-qPCR kits 7.7. 1000 Rxn One-step RT-qPCR kits 7.8. Above 1000 Rxn One-step RT-qPCR kits 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application 8.1. Virus Detection 8.2. Gene Expression Analysis 8.3. High-Sensitivity Detection & Quantification of RNA 8.4. Genetic Profiling 8.5. Mutation Detection 8.6. Multiplexing 8.7. Single Cell RT-PCR 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Detection 9.1. Probe-based Detection 9.2. Dye Based Detection 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User 10.1. Hospitals 10.2. Diagnostic Laboratories 10.3. Reference Laboratories 10.4. Academic and Research Institutes 10.5. Others Facilities 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 11.1. North America 11.2. Latin America 11.3. East Asia 11.4. South Asia and Pacific 11.5. Western Europe 11.6. Eastern Europe 11.7. Middle East and Africa 12. North America Sales USD Million & Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Latin America Sales USD Million & Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. East Asia Sales USD Million & Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. South Asia & Pacific Sales USD Million & Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Western Europe Sales USD Million & Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Eastern Europe Sales USD Million & Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Middle East and Africa Sales USD Million & Volume (Units) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 19. Sales Forecast 2024 to 2034 by, Reaction, and Application for 30 Countries 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 21. Company Profile 21.1. Thermo Fisher Scientific Inc. 21.2. QIAGEN 21.3. Takara Bio Inc 21.4. Bio-Rad Laboratories, Inc 21.5. Promega Corporation 21.6. New England Biolabs 21.7. Fortis Life Sciences 21.8. Quantabio 21.9. BIO-HELIX 21.10. MP Biomedicals 21.11. Avantor, Inc. 21.12. Intact Genomics, Inc 21.13. Solis BioDyne 21.14. Applied Biological Materials Inc 21.15. Merck KGAA 21.16. TIANGEN Biotech(Beijing)Co., Ltd 21.17. EnzyQuest 21.18. Canvax 21.19. Zymo Research Corporation 21.20. NZYtech 21.21. Abbexa 21.22. Boca Scientific Inc 21.23. GeneDireX, Inc.
Explore Healthcare Insights
View Reports
One Step RT-qPCR Kits Market
